Navigation Links
Sangamo BioSciences Provides Update on Phase 1 Safety Trial of SB-728-T for HIV/AIDS
Date:11/18/2009

RICHMOND, Calif., Nov. 18 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that data from the University of Pennsylvania investigator sponsored Phase 1 safety study of Sangamo's zinc finger nuclease (ZFN) based product, SB-728-T, for HIV/AIDS were inadvertently and prematurely disclosed on the internet.

Data were presented in a student course at the University of Pennsylvania School of Medicine from a single subject treated with SB-728-T who, as part of the study, began a structured treatment interruption (STI) from his antiviral drug therapy four weeks after SB-728-T treatment. This subject was reported to have stable CD4+ and ZFN-modified T-cell levels and an undetectable viral load one month post STI initiation. Previous studies have shown that in subjects undergoing an STI, the average time to detection of an increase in viral load is two to four weeks. While this subject continues to demonstrate stable CD4+ T-cell counts and stable levels of ZFN-modified T-cells, by six weeks post STI initiation the subject had a detectable viral load.

As previously stated, the company and the University of Pennsylvania intend to provide updates on the two ongoing Phase 1 SB-728-T trials only at appropriate scientific or medical meetings.

About Sangamo

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development program is currently in Phase 2 clinical trials for evaluation of safety and clinical effect in patients with diabetic neuropathy and ALS. Sangamo also has two Phase 1 clinical trials to evaluate safety and clinical effect of a ZFP Therapeutic for the treatment of HIV/AIDS. Other therapeutic development programs are focused o
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2

Related biology technology :

1. Sangamo BioSciences Announces Presentation at Merriman Curhan Fords Investor Summit 2009
2. Sangamo BioSciences Announces Third Quarter 2009 Conference Call and Webcast
3. Sangamo Announces Pricing of Public Offering of Common Stock
4. Sigma-Aldrich(R) and Sangamo BioSciences Announce Major Expansion of ZFP Technology License Agreement
5. Sangamo BioSciences Announces Presentation at the UBS Global Life Sciences Conference
6. Sangamos Zinc Finger Nuclease Technology Used to Efficiently Modify Human Stem Cells
7. Sangamo BioSciences Reports Second Quarter 2009 Financial Results
8. Sangamo BioSciences Announces Second Quarter 2009 Conference Call and Webcast
9. Sangamo BioSciences Announces Presentation at the Needham Life Sciences Conference
10. Sangamo BioSciences Receives $100,000 Grand Challenges Explorations Grant for Innovative Global Health Research
11. Sangamo BioSciences Announces Publication in Nature of the Use of Zinc Finger Nucleases to Accelerate Precision Trait Stacking in Commercial Crop Species
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... The Oklahoma tornado left the state ... mayor of Moore, one of the heavily damaged towns, proposed ... from cnn.com. Reaching out to also be of help, My ... Shield to counter the looming mold problem. , The ... 2013, caused 24 deaths, My Cleaning Products shared. Ten of ...
(Date:5/24/2013)... Vestiage, Inc. (stock symbol "VEST") a publicly ... and development, sales and marketing of premium branded ... that it is awarding exclusive Vestiage territories in ... Skin Illuminating Facial Care. Qualified applicants can request ... email to info(at)vestiageinc(dot)com and putting RELUMA in the ...
(Date:5/24/2013)... May 24, 2013 Quincy Bioscience, ... and development of calcium-binding proteins to support healthy ... safety assessment study of apoaequorin in ... published for the British Industrial Biological Research Association. ... to investigate potential adverse effects, if any, of ...
(Date:5/23/2013)... CAMBRIDGE, England , May 24, 2013 ... von Mundipharma angefertigt – Bei der ... Version , 91 % der Teilnehmer einer ... obwohl nur 20 % laut GINA [*] -Definition [1] ... zeigt, dass Menschen mit Asthma generell einer von vier ...
Breaking Biology Technology:Mayor of Oklahoma-Tornado-Impaired Town Proposes Storm Shelter Bill, My Cleaning Products Offers Complimentary Molderizer and Safe Shield to Help Victim with Looming Mold 2Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 2Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 3Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 4Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 5Safety Assessment Study of Apoaequorin Published in Food and Chemical Toxicology 2Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 2Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 3Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 4Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 5Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 6Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 7
... Cardium Health, AirLogix, and Work/Life Innovations into Next Generation ... ... Company, BEDFORD, Mass., March 4 CaseNET, Inc., a provider ... of Centene Corporation (NYSE: CNC ), has selected,the CaseNET platform ...
... - Two new independent non-executive directors added to Board with ... ... Eutick, OAM appointed independent non-executive Chairman, BRISBANE, Australia, March ... the,appointment of John Lee and Robert Williamson to the Company,s ...
... SOUTH SAN FRANCISCO, Calif., March 4 Sunesis,Pharmaceuticals, ... developing novel anticancer therapeutics, will present data at ... by the Society of,Gynecologic Oncologists (SGO). This year,s ... Tampa Convention Center in Tampa, Fla., Interim ...
Cached Biology Technology:Nurtur(TM) Selects CaseNET to Enable Integrated Health and Life Management Capabilities 2Progen Expands Board of Directors 2Progen Expands Board of Directors 3Progen Expands Board of Directors 4Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Women's Cancer 2
(Date:5/23/2013)... , Automated conserved noncoding sequence ... evolution among grasses , Within the genome of ... that undergo little change in position and sequence over ... proteins. Some of these evolutionarily stable sequences, so-called conserved ... of other genes or the condensation of chromosomes, but ...
(Date:5/23/2013)... said to be the world,s most popular fruit, can ... research with purple GM varieties. , "Working with ... by the addition of a specific compound, allows us ... said Professor Cathie Martin from the John Innes Centre. ... with better flavour, health and shelf life characteristics because ...
(Date:5/23/2013)... Wash. Pacific Northwest National Laboratory honored more ... commercialization of intellectual property at PNNL,s annual Intellectual ... , The Department of Energy national laboratory named ... for his work developing battery materials that can ... the electrical grid, and reduce the time it ...
Breaking Biology News(10 mins):Frontiers news briefs: May 23 2Frontiers news briefs: May 23 3The world's favorite fruit only better-tasting and longer-lasting 2PNNL staff recognized for scientific accomplishments, moving technologies into the marketplace 2
... antibody targeting a well known cell surface protein inhibited ... of the disease that did not respond to hormone ... UCLA Department of Urology and UCLA,s Jonsson Comprehensive Cancer ... N-cadherin, is up regulated or turned on in prostate ...
... This release is available in French . , Frank ... table would make people more aggressive, not less. After all, dont ... a game in hopes of pumping them up? And what about ... who dares take their meat away from them? Wouldnt that go ...
... Miss. A summit that,s both scientific conference and ... front lines of fighting obesity and related metabolic diseases ... sponsored by the University of Mississippi Medical Center and ... the Jackson Convention Complex. Obesity and related ...
Cached Biology News:UCLA researchers discover a potential target for therapy for patients with a deadly prostate cancer 2UCLA researchers discover a potential target for therapy for patients with a deadly prostate cancer 3Caveman behavioral traits might kick in at Thanksgiving table before eating 2Global Obesity Summit 2010 in Jackson addresses growing epidemic at ground zero 2Global Obesity Summit 2010 in Jackson addresses growing epidemic at ground zero 3Global Obesity Summit 2010 in Jackson addresses growing epidemic at ground zero 4Global Obesity Summit 2010 in Jackson addresses growing epidemic at ground zero 5
... Buffers are membrane-filtered isotonic and enzyme-free ... and cell-conditioning agents in either Ca2+- ... or Ca2+- and Mg2+-free phosphate-buffered ... cells from support substrates and each ...
... Dissociation Buffers are membrane-filtered isotonic and ... agents and cell-conditioning agents in either ... solution or Ca2+- and Mg2+-free ... mammalian cells from support substrates and ...
... Antibody Modification Services ... including antibody labeling and antibody fragmentation. ... provides signals for visualization and quantitation ... assays, it is preferable to use ...
Carbonate-Bicarbonate Buffer Capsules. For use in coating ELISA plates. Dissolve contents of 1 capsule in 100 ml deionized water to yield 0.05 M carbonate-bicarbonate buffer, pH 9.6....
Biology Products: